Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: Future directions

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Poly(ADP-ribose) polymerase (PARP) activation plays a role in the pathogenesis of various cardiovascular and inflammatory diseases. Reactive oxygen and nitrogen species induce DNA single strand breaks, which serve as obligatory triggers for the activation of PARP. Pharmacological inhibitors of PARP attenuate ischemic and inflammatory cell and organ injury, and this property of the PARP inhibitors can be exploited for the experimental therapy of disease. As several classes of PARP inhibitors move towards clinical development, or have already entered clinical trials, we expect that in the upcoming few years, clinical proof of PARP inhibitors' therapeutic effect will be obtained in human disease. Acute, life-threatening cardiovascular diseases (myocardial infarction, cardiopulmonary bypass in high-risk patients, and other, severe forms of ischemia-reperfusion to other organs including stroke and thoracoabdominal aneurysm repair) represent some of the initial development indications for PARP inhibitors.

Original languageEnglish (US)
Pages (from-to)301-303
Number of pages3
JournalCurrent Vascular Pharmacology
Volume3
Issue number3
DOIs
StatePublished - Jul 2005
Externally publishedYes

Fingerprint

Poly(ADP-ribose) Polymerases
Pharmacology
Cardiovascular Diseases
Reactive Nitrogen Species
Single-Stranded DNA Breaks
Investigational Therapies
Therapeutic Uses
Cardiopulmonary Bypass
Reperfusion
Aneurysm
Reactive Oxygen Species
Ischemia
Stroke
Myocardial Infarction
Poly(ADP-ribose) Polymerase Inhibitors
Direction compound
Clinical Trials
Wounds and Injuries

Keywords

  • Acute
  • Apoptosis
  • Blood vessels
  • Chronic
  • DNA repair
  • Drug development
  • Inflammation
  • Myocardial infarction
  • Necrosis
  • Stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders : Future directions. / Szabo, Csaba.

In: Current Vascular Pharmacology, Vol. 3, No. 3, 07.2005, p. 301-303.

Research output: Contribution to journalArticle

@article{f0bcb4b524c8402694dab460587a1ba1,
title = "Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: Future directions",
abstract = "Poly(ADP-ribose) polymerase (PARP) activation plays a role in the pathogenesis of various cardiovascular and inflammatory diseases. Reactive oxygen and nitrogen species induce DNA single strand breaks, which serve as obligatory triggers for the activation of PARP. Pharmacological inhibitors of PARP attenuate ischemic and inflammatory cell and organ injury, and this property of the PARP inhibitors can be exploited for the experimental therapy of disease. As several classes of PARP inhibitors move towards clinical development, or have already entered clinical trials, we expect that in the upcoming few years, clinical proof of PARP inhibitors' therapeutic effect will be obtained in human disease. Acute, life-threatening cardiovascular diseases (myocardial infarction, cardiopulmonary bypass in high-risk patients, and other, severe forms of ischemia-reperfusion to other organs including stroke and thoracoabdominal aneurysm repair) represent some of the initial development indications for PARP inhibitors.",
keywords = "Acute, Apoptosis, Blood vessels, Chronic, DNA repair, Drug development, Inflammation, Myocardial infarction, Necrosis, Stroke",
author = "Csaba Szabo",
year = "2005",
month = "7",
doi = "10.2174/1570161054368553",
language = "English (US)",
volume = "3",
pages = "301--303",
journal = "Current Vascular Pharmacology",
issn = "1570-1611",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders

T2 - Future directions

AU - Szabo, Csaba

PY - 2005/7

Y1 - 2005/7

N2 - Poly(ADP-ribose) polymerase (PARP) activation plays a role in the pathogenesis of various cardiovascular and inflammatory diseases. Reactive oxygen and nitrogen species induce DNA single strand breaks, which serve as obligatory triggers for the activation of PARP. Pharmacological inhibitors of PARP attenuate ischemic and inflammatory cell and organ injury, and this property of the PARP inhibitors can be exploited for the experimental therapy of disease. As several classes of PARP inhibitors move towards clinical development, or have already entered clinical trials, we expect that in the upcoming few years, clinical proof of PARP inhibitors' therapeutic effect will be obtained in human disease. Acute, life-threatening cardiovascular diseases (myocardial infarction, cardiopulmonary bypass in high-risk patients, and other, severe forms of ischemia-reperfusion to other organs including stroke and thoracoabdominal aneurysm repair) represent some of the initial development indications for PARP inhibitors.

AB - Poly(ADP-ribose) polymerase (PARP) activation plays a role in the pathogenesis of various cardiovascular and inflammatory diseases. Reactive oxygen and nitrogen species induce DNA single strand breaks, which serve as obligatory triggers for the activation of PARP. Pharmacological inhibitors of PARP attenuate ischemic and inflammatory cell and organ injury, and this property of the PARP inhibitors can be exploited for the experimental therapy of disease. As several classes of PARP inhibitors move towards clinical development, or have already entered clinical trials, we expect that in the upcoming few years, clinical proof of PARP inhibitors' therapeutic effect will be obtained in human disease. Acute, life-threatening cardiovascular diseases (myocardial infarction, cardiopulmonary bypass in high-risk patients, and other, severe forms of ischemia-reperfusion to other organs including stroke and thoracoabdominal aneurysm repair) represent some of the initial development indications for PARP inhibitors.

KW - Acute

KW - Apoptosis

KW - Blood vessels

KW - Chronic

KW - DNA repair

KW - Drug development

KW - Inflammation

KW - Myocardial infarction

KW - Necrosis

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=21644467334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21644467334&partnerID=8YFLogxK

U2 - 10.2174/1570161054368553

DO - 10.2174/1570161054368553

M3 - Article

C2 - 16026326

AN - SCOPUS:21644467334

VL - 3

SP - 301

EP - 303

JO - Current Vascular Pharmacology

JF - Current Vascular Pharmacology

SN - 1570-1611

IS - 3

ER -